ARQT
Arcutis Biotherapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -5.4% · net new positions -6.2% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 14.37K | $352,080 | n/a | −1 |
| Q2 2026 | 104 | +8 | 69.45M | $1.82B | +11 | −3 |
| Q1 2026 | 99 | +1 | 69.94M | $1.65B | +6 | −6 |
| Q4 2025 | 97 | +2 | 70.50M | $2.05B | +3 | n/a |
| Q3 2025 | 16 | 0 | 32.55M | $613.65M | +1 | −2 |
| Q2 2025 | 14 | -2 | 28.30M | $396.73M | n/a | −2 |
| Q1 2025 | 13 | 0 | 11.91M | $186.25M | +1 | −1 |
| Q4 2024 | 13 | +1 | 15.11M | $210.56M | +1 | n/a |
| Q3 2024 | 11 | +1 | 9.54M | $88.77M | +2 | −1 |
| Q2 2024 | 10 | n/a | 8.25M | $76.75M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 8.57M | +0.5% | $161.62M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 2 | The Vanguard Group ✦ (passive) | 7.15M | +1.4% | $134.70M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 3 | State Street Global Advisors ✦ (passive) | 4.64M | +2.5% | $87.49M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Morgan Stanley ✦ | 4.28M | n/a | $80.61M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 5 | Geode Capital Management ✦ (passive) | 2.61M | +0.9% | $49.14M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 6 | D. E. Shaw & Co. ✦ | 2.12M | -2.0% | $39.94M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 7 | Goldman Sachs Group ✦ | 1.80M | n/a | $34.02M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 8 | AQR Capital Management ✦ | 441.31K | +17.6% | $8.32M | 0.0% | ▲ Add | 6 | SEC ↗ ×5 |
| 9 | JPMorgan Chase ✦ | 201.59K | n/a | $3.80M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 10 | Citadel Advisors ✦ | 177.27K | +21.8% | $3.34M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 11 | Fidelity (FMR) ✦ | 167.97K | +11.4% | $3.17M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 12 | Millennium Management ✦ | 150.10K | -83.5% | $2.83M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 13 | Two Sigma Investments ✦ | 95.43K | +33.1% | $1.80M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 87.80K | +4.5% | $1.66M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 15 | Wellington Management ✦ | 46.39K | +4.8% | $874,433 | 0.0% | ▲ Add | 6 | SEC ↗ ×4 |
| 16 | Marshall Wace ✦ | 18.30K | New | $344,955 | 0.0% | New | 1 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $344,955 | 0.0% |
Exited
| Point72 Asset Management | $20.83M | was 0.1% |
| Norges Bank | $2.45M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 267 holders, 132.09M shares, $3.07B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 4.73K sh · $127,325
Officer · 3.67K sh · $91,853
Director · 4.73K sh · $114,371
Officer · 9.99K sh · $249,986
Director · 11.15K sh · $279,028
Director · 27.05K sh · $677,095
Director · 1.07K sh · $27,912
Officer · 1.70K sh · $45,819
Director · 4.73K sh · $123,835
Officer · 6.70K sh · $174,767
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology